X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TXA127 (talfirastide) is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1‐7). It is under phase 2 clinical development for ischemic stroke recovery.
Lead Product(s): Talfirastide
Therapeutic Area: Neurology Product Name: TXA127
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
The trial will test several compounds, each against a placebo group. The TXA127 segment will involve 300 patients treated with the peptide and will be conducted at some 60 sites nationwide.
Lead Product(s): Angiotensin (1-7)
Therapeutic Area: Infections and Infectious Diseases Product Name: TXA127
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Researchers at two major medical centers in Israel, Rambam Medical Health Care Campus and Ziv Medical Center, have initiated a Phase 2 clinical trial of a promising new treatment for COVID-19. These trials are testing TXA27, a compound with an established safety profile.
Lead Product(s): Angiotensin (1-7)
Therapeutic Area: Infections and Infectious Diseases Product Name: TXA127
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
The double-blind, placebo-controlled trial will recruit 100 patients with COVID-19 who require oxygen but are not in the ICU. The endpoints include incidence of renal failure and incidence of respiratory failure.
Lead Product(s): Angiotensin (1-7)
Therapeutic Area: Infections and Infectious Diseases Product Name: TXA127
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Constant Therapeutics' peptide drug TXA127 will be tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU).
Lead Product(s): Angiotensin (1-7)
Therapeutic Area: Infections and Infectious Diseases Product Name: TXA127
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
